Topics:
Breast Cancer • Medical Oncology • NCI-CCC Tumor Board Question • University of Wisconsin • HR+
Would you offer additional therapy for a patient with HR+ breast cancer on AI+OS who is found to have a focus of ovarian metastasis at the time of elective BSO?
Additionally, would the finding of any mutations, such as ESR1, change your recommendation?
Answer from: Medical Oncologist at Community Practice
Technically this finding will make the patient status as stage IV. Of course, I assume that special consultation was made to ensure the breast primary, instead of ovarian primary. Given the need for BSO, I can see that the patient would be a pre-menopausal young woman, thus genetic testing would be ...
Sign in or Register to read more
Answer from: Medical Oncologist at Academic Institution
I agree with the previous answer. In patients who underwent BSO for solitary metastatic deposit in the ovary, and who have no other radiographic evidence of metastatic disease, I would lean towards single agent aromatase inhibitor and continue it until disease progression. Upon disease progression, ...